200 related articles for article (PubMed ID: 32632237)
21. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Brookhart MA; Avorn J; Katz JN; Finkelstein JS; Arnold M; Polinski JM; Patrick AR; Mogun H; Solmon DH
Am J Med; 2007 Mar; 120(3):251-6. PubMed ID: 17349448
[TBL] [Abstract][Full Text] [Related]
22. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
23. Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy : A Propensity Score-Matched Cohort Study.
Hayes KN; Brown KA; Cheung AM; Kim SA; Juurlink DN; Cadarette SM
Ann Intern Med; 2022 Mar; 175(3):335-343. PubMed ID: 35007149
[TBL] [Abstract][Full Text] [Related]
24. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
Eiken PA; Prieto-Alhambra D; Eastell R; Abrahamsen B
Osteoporos Int; 2017 Oct; 28(10):2921-2928. PubMed ID: 28664276
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
26. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.
Anagnostis P; Paschou SA; Gkekas NN; Artzouchaltzi AM; Christou K; Stogiannou D; Vryonidou A; Potoupnis M; Goulis DG
Endocrine; 2018 Jun; 60(3):373-383. PubMed ID: 29411304
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of antiresorptive medications in women on long-term dialysis after hip fracture: A population-based cohort study.
Lin YC; Lee TC; Chen CY; Lin SJ; Hwang SJ; Lin MY
PLoS One; 2020; 15(9):e0238248. PubMed ID: 32877436
[TBL] [Abstract][Full Text] [Related]
30. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
[TBL] [Abstract][Full Text] [Related]
31. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
32. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
Turbí C; Herrero-Beaumont G; Acebes JC; Torrijos A; Graña J; Miguélez R; Sacristán J; Marín F
Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
[TBL] [Abstract][Full Text] [Related]
33. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group.
Cummings SR; Palermo L; Browner W; Marcus R; Wallace R; Pearson J; Blackwell T; Eckert S; Black D
JAMA; 2000 Mar; 283(10):1318-21. PubMed ID: 10714731
[TBL] [Abstract][Full Text] [Related]
34. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
35. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.
Thompson M; Pasquale M; Grima D; Moehrke W; Kruse HP
Value Health; 2010; 13(1):46-54. PubMed ID: 19883401
[TBL] [Abstract][Full Text] [Related]
36. Alendronate Use and the Risk of Nonvertebral Fracture During Glucocorticoid Therapy: A Retrospective Cohort Study.
Bergman J; Nordström A; Nordström P
J Clin Endocrinol Metab; 2018 Jan; 103(1):306-313. PubMed ID: 29126139
[TBL] [Abstract][Full Text] [Related]
37. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
Chiu WY; Lee JJ; Tsai KS
J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
[TBL] [Abstract][Full Text] [Related]
38. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Adami S; Isaia G; Luisetto G; Minisola S; Sinigaglia L; Gentilella R; Agnusdei D; Iori N; Nuti R;
J Bone Miner Res; 2006 Oct; 21(10):1565-70. PubMed ID: 16995811
[TBL] [Abstract][Full Text] [Related]
39. Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
Pasion EG; Sivananthan SK; Kung AW; Chen SH; Chen YJ; Mirasol R; Tay BK; Shah GA; Khan MA; Tam F; Hall BJ; Thiebaud D
J Bone Miner Metab; 2007; 25(2):105-13. PubMed ID: 17323180
[TBL] [Abstract][Full Text] [Related]
40. Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone.
Axelsson KF; Nilsson AG; Wedel H; Lundh D; Lorentzon M
JAMA; 2017 Jul; 318(2):146-155. PubMed ID: 28697254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
